Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

Duvelisib (Copiktra(®)) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, Daniel A., Sagrillo, Fernanda S., Fraga, Carlos A. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631818/
https://www.ncbi.nlm.nih.gov/pubmed/31064155
http://dx.doi.org/10.3390/ph12020069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631818/
https://www.ncbi.nlm.nih.gov/pubmed/31064155
http://dx.doi.org/10.3390/ph12020069

Ejemplares similares